Skip to main content
Log in

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3

References

  1. Hasle H . Pattern of malignant disorders in individuals with Down′s syndrome. Lancet Oncol 2001; 2: 429–436.

    Article  CAS  PubMed  Google Scholar 

  2. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M . AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355–1360.

    Article  CAS  Google Scholar 

  3. Hitzler JK, Zipursky A . Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11–20.

    Article  CAS  Google Scholar 

  4. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005; 106: 4043–4049.

    Article  CAS  PubMed  Google Scholar 

  5. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  Google Scholar 

  6. Klusmann JH, Reinhardt D, Hasle H, Kaspers GJ, Creutzig U, Hahlen K et al. Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome. Leukemia 2007; 21: 1584–1587.

    Article  CAS  PubMed  Google Scholar 

  7. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down′s syndrome. Lancet 2008; 372: 1484–1492.

    Article  CAS  Google Scholar 

  8. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 930–932.

    Article  CAS  Google Scholar 

  9. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414–9418.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants of COG: CA30969, CA29139, CA13539, CA98543 and CA98413.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C M Zwaan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blink, M., Buitenkamp, T., van den Heuvel-Eibrink, M. et al. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 25, 1365–1368 (2011). https://doi.org/10.1038/leu.2011.86

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.86

  • Springer Nature Limited

This article is cited by

Navigation